Decision letter: A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates

Similar Works

Action	Title	Year	Authors
+	Author response: A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates	2020	Dennis Wang James Hensman Ginte Kutkaite Tzen S. Toh Ana Galhoz Howard Lightfoot Wanjuan Yang Maryam Soleimani Syd Barthorpe Tatiana Mironenko
+ PDF Chat	Response to uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group – author’s reply	2023	Milou A. Hogervorst Rick A. Vreman Inkatuuli Heikkinen Wija Oortwijn
+	Use of statistical and pharmacokinetic–pharmacodynamic modeling and simulation to improve decision-making: A section summary report of the trends and innovations in clinical trial statistics conference	2017	Holly Kimko Seth Berry Michael O’Kelly Nitin Mehrotra Matthew M. Hutmacher Venkat Sethuraman
+ PDF Chat	Confidence and Prediction Intervals for Pharmacometric Models	2018	Anne Kümmel Peter L. Bonate Jasper Dingemanse Andreas Krause
+	Quantitative methods to support drug benefit-risk assessment	2014	Ola Caster
+	A Comprehensive Toolbox to Facilitate Quantitative Decision Science in Drug Development: A web-based R shiny application GOahead	2022	Bo Wei Weibin Zhong Rong Liu Alan H.B. Wu Alan Y.S. Chiang Michael Branson Nanxiang Ge
+	Risk-benefit analysis methods for pharmaceutical decision-making–where are we now?	2006	Brett Hauber F. Reed Johnson Elizabeth Andrews
+	Variability and uncertainty: interpretation and usage of pharmacometric simulations and intervals	2022	Chuanpu Hu
+	Bayesian decision-theoretic method and semi-parametric approach with applications in clinical trial designs and longitudinal studies	2013	Fei Jiang
+	The Case for a Bayesian Approach to Benefit-Risk Assessment: Overview and Future Directions	2017	Maria J. Costa Weili He Yannis Jemiai Yueqin Zhao Carl Di Casoli
+	Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions	1993	Rosemarie Mick Mark J. Ratain
+	Risk of false pharmaceutical equivalence (non-equivalence) decisions due to measurement uncertainty	2021	Maria Luiza de Godoy Bertanha Felipe Rebello Lourenço
+	A causal-inference approach for the validation of surrogate endpoints based on information theory and sensitivity analysis	2016	Ariel Alonso Wim Van der Elst Geert Molenberghs Marc Buyse Tomasz Burzykowski
+ PDF Chat	Decision curve analysis: a technical note	2018	Zhongheng Zhang Valentin Rousson Wen‐Chung Lee Cyril Ferdynus Mingyu Chen Xin Qian Yizhan Guo
+	Clinical Decision Making Using Pharmacokinetic and Pharmacodynamic Data	1985	B. Whiting A. W. Kelman
+	Pharmacometrics for Regulatory Decision Making	2011	Efthymios Manolis Ralf Herold
+	A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group	2010	Jeff J. Guo Swapnil Pandey John Doyle Boyang Bian Y. Lis Dennis W. Raisch
+	Modelling Individual Response to Treatment and Its Uncertainty:A Review of Statistical Methods and Challenges for Future Research	2020	Ulrich Mansmann Anne‐Laure Boulesteix
+	Real‐World Data and Clinical Pharmacology: A Regulatory Science Perspective	2019	Qi Liu Anuradha Ramamoorthy Shiew‐Mei Huang
+ PDF Chat	Introductory Chapter: Overview of Data and Decision Sciences – Recent Advances and Applications	2023	Tien M. Nguyen

Works That Cite This (0)

Action	Title	Year	Authors

Works Cited by This (0)

Action	Title	Year	Authors